SAWT BEIRUT INTERNATIONAL

| 14 April 2024, Sunday |

Japan approves rheumatoid drug Baricitinib for COVID-19 patients

Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.

    Source:
  • Reuters